ELEVATE: Study design of the observational study of bimekizumab in adult patients with moderate to severe plaque psoriasis

被引：0

作者：

Asadullah, Khusru ^{[1
,2
]}

Stavermann, Thomas ^{[3
]}

Heidbrede, Tanja ^{[4
]}

Schlueter, Kathrin ^{[5
]}

Fierens, Frederik ^{[6
]}

Thaci, Diamant ^{[7
]}

von Kiedrowski, Ralph Michael ^{[8
]}

机构：

[1] Hautarztpraxis, Potsdam, Germany

[2] Hautklin Charite, Berlin, Germany

[3] MVZ Hautzentrum Gropiuspas GmbH, Berlin, Germany

[4] UCB BioSci GmbH, Monheim, Germany

[5] UCB Pharma GmbH, Monheim, Germany

[6] UCB Pharma srl, Brussels, Belgium

[7] Univ Klinikum Schleswig Holstein, Inst Entzundungsmed, Campus Lubeck, Lubeck, Germany

[8] CMS3 GmbH, Selters, Germany

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P116

引用

页码：81 / 82

页数：2

共 50 条

[31] Talarozole for moderate to severe plaque psoriasis - results of a dose-finding study
Griffiths, C.
van de Kerkhof, P.
Steijlen, P.
ShrooC, B.
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 : S60 - S60
[32] Clinical Study Results of Desominietasone Spray, 0.25% in Moderate to Severe Plaque Psoriasis
Kircik, Leon
Lebwohl, Mark G.
Del Rosso, James Q.
Bagel, Jerry
Gold, Linda Stein
Weiss, Jonathan S.
[J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (12) : 1404 - 1410
[33] Remicade® in moderate to severe plaque psoriasis
Ortonne, J. -P.
[J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2006, 133 (05): : 1S13 - 1S17
[34] DOSE OPTIMIZATION OF SECUKINUMAB IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: OPTIMISE STUDY
Reich, Kristian
Puig, Lluis
Szepietowski, Jacek
Paul, Carle
Rissler, Michael
Sieder, Christian
Orsenigo, Roberto
Chaouche-Teyara, Kamel
[J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 11 - 12
[35] Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study
Ding, Yangfeng
Li, Wei
Guan, Xin
Liu, Na
Zhou, Ying
Li, Gaojie
Wang, Xiaohua
Wang, Zhidong
Xiao, Xiao
Yang, Bin
Lv, Chengzhi
Zhang, Chunlei
Shi, Yuling
[J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (10): : 1803 - 1814
[36] COMPLETE SKIN CLEARANCE IS NOT ATTAINED BY MOST PATIENTS RECEIVING BIOLOGICS FOR MODERATE TO SEVERE PLAQUE PSORIASIS: INTERIM RESULTS OF AN INTERNATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY
Augustin, M.
Lacour, J.
Reich, K.
Horne, L.
Williams, A.
Horton, J.
Slynn, G.
Hammond, E. R.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A575 - A575
[37] Estimation of the prevalence of latent tuberculosis infection in patients with moderate to severe plaque psoriasis in Spain: The Latent study
Ribera, M.
Zulaica, A.
Pujol, C.
Alonso, M. L.
Rodriguez, I. M.
Garcia-Calvo, C.
[J]. ACTAS DERMO-SIFILIOGRAFICAS, 2015, 106 (10): : 823 - 829
[38] Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis
Cather, Jennifer Clay
Young, Chaney T.
Young, Melody S.
Cather, J. Christian
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (08) : 983 - 990
[39] Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study
Galica, Katarzyna
Lesiak, Aleksandra
Ciazynska, Magdalena
Noweta, Marcin
Bednarski, Igor
Narbutt, Joanna
[J]. POSTEPY DERMATOLOGII I ALERGOLOGII, 2021, 38 (06): : 973 - 978
[40] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
Prieto-Perez, Rocio
Llamas-Velasco, Mar
Cabaleiro, Teresa
Solano-Lopez, Guillermo
Marquez, Beatriz
Roman, Manuel
Ochoa, Dolores
Talegon, Maria
Dauden, Esteban
Abad-Santos, Francisco
[J]. PHARMACOGENOMICS, 2017, 18 (02) : 157 - 164

← 1 2 3 4 5 →